References
- Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–2405.
- Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189–199.
- Brunning RD, Orazi A, Germing U, et al. Myelodysplastic syndromes/neoplasms, overview. In: Swerdlow SH, Campo E, Harris NL, et al. editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon (France): IARC; 2008. 88–93.
- Malcovati L, Hellstrom-Lindberg E, Bowen D, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013;122:2943–2964.
- Mittelman M. The myelodysplastic syndromes-1990. Isr J Med Sci. 1990;26:468–478.
- Mittelman M, Lessin LS. Myelodysplasia (Preleukemia). In: Moossa AR, Schimpff SC, Robson MC, eds. Comprehensive textbook of oncology. 2nd ed. Baltimore (MD): Williams & Wilkins; 1991:1232–44.
- Aul C, Germing U, Gattermann N, et al. Increasing incidence of myelodysplastic syndromes: real or fictitious? Leuk Res. 1998;22:93–100.
- de Swart L, Smith A, Johnston TW, et al. Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry. Br J Haematol. 2015;170:372–383.
- Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088.
- Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–2465.
- Lichtman MA, Liesveld JL. Myelodysplastic syndromes (clonal cytopenias and oligoblastic leukemia). In: Lichtman MA, Beutler E, Kipps TJ, Seligson U, Kaushansky K, Prchal JT, editors. Williams hematology. 7th ed. New York (NY): McGraw Hill; 2006. p.1157–1181.
- Ryan DH, Cohen HJ. Bone marrow examination. In: Hoffman R, Benz Jr. EJ, Shattil SJ, et al. editors. Hematology-basic principles and practice. 4th ed. Philadelphia (PA): Elsevier-Churchill-Livingstone; 2005. p. 2656–2671.
- Ryan DH, Felgar RE. Examination of the marrow. In: Lichtman MA, Beutler E, Kipps TJ, Seligson U, Kaushansky K, Prchal JT, editors. Williams hematology. 7th ed. New York (NY): McGraw Hill; 2006. p. 21–31.
- Fenaux P, Ades L. How we treat lower-risk myelodysplastic syndromes. Blood. 2013;121:4280–4286.
- Gangat N, Patnaik MM, Tefferi A. Myelodysplastic syndromes: contemporary review and how we treat. Am J Hematol. 2016;91:76–89.
- List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355:1456–1465.
- Patnaik MM, Tefferi A. Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management. Am J Hematol. 2017;92:297–310.
- Steensma DP. Myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc. 2015;90:969–983.
- Suzuki Y, Tomita A, Nakamura F, et al. Peripheral blood cell-free DNA is an alternative tumor DNA source reflecting disease status in myelodysplastic syndromes. Cancer Sci. 2016;107:1329–1337.
- Yeh P, Dickinson M, Ftouni S, et al. Molecular disease monitoring using circulating tumor DNA in myelodysplastic syndromes. Blood. 2017;129:1685–1690.